SVB Leerink analyst Mani Foroohar raised his price target for Alnylam (ALNY) to $70 from $65 after the company announced a collaboration with Regeneron (REGN) to develop and commercialize RNAi therapeutics with a focus on CNS and ocular indications, along with liver-directed NASH therapies and cemdisiran in combination with pozelimab. The analyst believes the terms of the deal, which includes a $400M upfront payment and a $400M equity investment in Alnylam at $90/share, are favorable for Alnylam. Foroohar reiterates a Market Perform rating on Alnylam's shares.